Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Vanier Canada Graduate Scholarships - Doctoral

University of Alberta

$50,000.00

Antimicrobial Agents Based on Amino-Vinyl Cysteine Lantibiotics

EF 2012-13

Résumé
In 2005, 12,000 patients in the USA died after becoming infected with methicillin-resistant S. aureus (MRSA), costing the health system a total of $9.5 billion. The emergence of multi-drug resistant bacteria in the clinical setting poses a growing threat to human health and emphasizes the need to develop new classes of antibiotics. Lantibiotics are peptides that contain special residues called lanthionines and are produced by bacteria. These peptides exhibit potent antimicrobial activity against a wide range of Gram-positive bacteria, including MRSA (e.g. Mu1140, a derivative of gallidermin currently in phase 1 clinical trials). An especially promising class of lantibiotics are those containing an amino vinylcysteine unit, such as gallidermin. However, their synthesis is complex. The recently developed methods to efficiently make lantibiotics using solid-phase peptide synthesis (SPPS), pioneered by our research group, enables the generation of new analogues. I will use SPPS to make amino vinylcysteine lantibiotics, such as gallidermin and its analogues, with improved activity and stability. The synthesised analogues will then be tested for efficacy as broad spectrum antibiotics against pathogens resistant to current therapy, including MRSA and vancomycin-resistant enterococci (VRE). The development of these antibiotics is crucial for the treatment of bacterial infections that claim thousands of lives in North America every year.
Programme
Vanier Canada Graduate Scholarships - Doctoral
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
405722-2011
Name nom
Cochrane, Stephen
Department département
Chemistry
Organization id
9
Institution établissement
University of Alberta
Province en
Alberta
Province fr
Alberta
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2012
Competition year année de concours
2011
Award amount
50000
Program id
VCGS
Program name en
Vanier Canada Graduate Scholarships - Doctoral
Program name fr
Bourses d'études supérieures du Canada Vanier - Doctorat
Group en
Training programs
Group fr
Programmes de bourse
Committee code
1082
Committee name en
Vanier Selection Committee
Committee name fr
Comité de sélection Vanier
Area of application code
9999
Area of application group en
Not available
Area of application group fr
Non disponible
Area of application en
Not available
Area of application fr
Non disponible
Research subject code
3700
Research subject group en
Organic chemistry
Research subject group fr
Chimie organique
Research subject en
Organic chemistry
Research subject fr
Chimie organique
Partie
0
Application title
Antimicrobial Agents Based on Amino-Vinyl Cysteine Lantibiotics
Keyword
NSERC
Application summary
In 2005, 12,000 patients in the USA died after becoming infected with methicillin-resistant S. aureus (MRSA), costing the health system a total of $9.5 billion. The emergence of multi-drug resistant bacteria in the clinical setting poses a growing threat to human health and emphasizes the need to develop new classes of antibiotics. Lantibiotics are peptides that contain special residues called lanthionines and are produced by bacteria. These peptides exhibit potent antimicrobial activity against a wide range of Gram-positive bacteria, including MRSA (e.g. Mu1140, a derivative of gallidermin currently in phase 1 clinical trials). An especially promising class of lantibiotics are those containing an amino vinylcysteine unit, such as gallidermin. However, their synthesis is complex. The recently developed methods to efficiently make lantibiotics using solid-phase peptide synthesis (SPPS), pioneered by our research group, enables the generation of new analogues. I will use SPPS to make amino vinylcysteine lantibiotics, such as gallidermin and its analogues, with improved activity and stability. The synthesised analogues will then be tested for efficacy as broad spectrum antibiotics against pathogens resistant to current therapy, including MRSA and vancomycin-resistant enterococci (VRE). The development of these antibiotics is crucial for the treatment of bacterial infections that claim thousands of lives in North America every year.